小分子E26转化特异性抑制剂TK216减弱了儿科白血病的致癌性质
Ritul Sharma1, Chunfen Zhang1, Aru Narendran1
1Department of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, AB T2N 4N1, Canada.
Genes
|October 28, 2023
概括
小分子ETS抑制剂TK216通过诱导细胞死亡和抑制细胞迁移,在儿科白血病中表现出抗瘤作用. TK216是一种有前途的向治疗急性髓性白血病和B型淋巴细胞白血病.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- E26转化特异性 (ETS) 转录因子对于正常的血液形成至关重要.
- 异常的ETS活动与白血病的发病和进展有关.
- 准ETS因子为白血病提供了潜在的治疗策略.
研究的目的:
- 评估小分子ETS抑制剂TK216在儿童白血病中的抗瘤活性.
- 调查TK216疗效背后的机制.
- 评估TK216作为向治疗剂的潜力.
主要方法:
- 在小儿白血病细胞系和正常血液单核细胞上对TK216的体外评估.
- 评估TK216对细胞生长,细胞循环,细胞亡和迁移的影响.
- 研究TK216对关键蛋白质水平 (例如Mcl-1) 的影响及其与其他治疗剂的相互作用.
- 在有骨髓衍生条件介质的情况下评估TK216的影响.
主要成果:
- TK216表现出显著的抗瘤活性,包括生长抑制,细胞循环停止,亡诱导和儿童白血病细胞的迁移能力降低.
- TK216对正常血液单核细胞的毒性最小.
- 与5-阿扎西提丁一起进行原始化,增强了TK216的细胞毒性作用.
- TK216的目标是富含 purin 的 box1 (PU.1) 和剂量取决于降低 Mcl-1 蛋白质水平.
- 在骨髓衍生条件介质中,TK216增强了抗venetoclax细胞中Bcl-2抑制的作用和调节了白血病细胞存活率.
结论:
- TK216对儿科急性髓性白血病和B型淋巴细胞白血病表现出强大的抗白血病活性.
- TK216的机制涉及向PU.1并降低Mcl-1的调节,从而提高对其他疗法的敏感性.
- TK216是治疗特定类型白血病的有希望的向治疗候选药物.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K